drugset
drugset / Trial / NCT02581553

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

NCT02581553 ↗

Phase 1 Completed 116 enrolled Ardea Biosciences, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

Timeline

Start
2015-10
Primary completion
2016-07
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopurinol Small molecule 200 mg —
Subject Allopurinol Small molecule 300 mg —
Subject Lesinurad Small molecule 200 mg —

Indications

No indication recorded.